Hypercoagulability is a major complication seen in as many as 31% of patients with COVID-19. It leads to many life-threatening outcomes, pulmonary embolism being the most common thrombotic complication. Hypercoagulability is characterized by elevated Fibrinogen and D-dimer levels.<unk>  in COVID-19 must be differentiated from other diseases that cause disseminated intravascular coagulation (DIC). Prophylactic anticoagulation with low molecular weight heparin is given to all inpatients in the absence of active bleeding. Full dose anticoagulation is administered in patients with documented and confirmed venous thromboembolism (VTE) .
COVID-19-associated coagulopathy
COVID-19-associated cytokine storm
COVID-19-associated stroke
COVID-19-associated thrombocytopenia
COVID-19-associated cardiogenic shock
COVID-19-associated polyneuritis cranialis
COVID-19-associated neutrophilia
COVID-19-associated meningitis